From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research
International Journal of Molecular Sciences · 21.08.2023 · 24 (16) · 13021
DOI: 10.3390/ijms241613021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.08.2023. Verfasst von Andrew Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Applied Translational Genetics Group, Centre for Brain Research, School of Biological Sciences, The University of Auckland, Auckland 1010, New Zealan…. Hauptthemen laut MEDLINE: Huntington Disease, Heredodegenerative Disorders, Nervous System. Die Arbeit wurde bisher 166-mal zitiert (Crossref) und nennt 479 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New Zealand Ministry of Business Innovation and Employment, CHDI Foundation, Freemasons New Zealand, and New Zealand Ministry of Business Innovation and Employment funding for New Zealand–China Non-Communicable Diseases….
Abstract (Originalsprache)
Huntington’s disease (HD) is a debilitating neurodegenerative genetic disorder caused by an expanded polyglutamine-coding (CAG) trinucleotide repeat in the huntingtin (HTT) gene. HD behaves as a highly penetrant dominant disorder likely acting through a toxic gain of function by the mutant huntingtin protein. Widespread cellular degeneration of the medium spiny neurons of the caudate nucleus and putamen are responsible for the onset of symptomology that encompasses motor, cognitive, and behavioural abnormalities. Over the past 150 years of HD research since George Huntington published his description, a plethora of pathogenic mechanisms have been proposed with key themes including excitotoxicity, dopaminergic imbalance, mitochondrial dysfunction, metabolic defects, disruption of proteostasis, transcriptional dysregulation, and neuroinflammation. Despite the identification and characterisation of the causative gene and mutation and significant advances in our understanding of the cellular pathology in recent years, a disease-modifying intervention has not yet been clinically approved. This review includes an overview of Huntington’s disease, from its genetic aetiology to clinical presentation and its pathogenic manifestation. An updated view of molecular mechanisms and the latest therapeutic developments will also be discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Applied Translational Genetics Group, Centre for Brain Research, School of Biological Sciences, The University of Auckland, Auckland 1010, New Zealand.
ORCID-Profile: Andrew Jiang, Renee R Handley, Russell G Snell
Förderung
- New Zealand Ministry of Business Innovation and Employment
- CHDI Foundation, Freemasons New Zealand, and New Zealand Ministry of Business Innovation and Employment funding for New Zealand–China Non-Communicable Diseases…
Zitieren
APA
Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023). From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research. International Journal of Molecular Sciences, 24(16), 13021. https://doi.org/10.3390/ijms241613021
Vancouver
Jiang A, Handley RR, Lehnert K, Snell RG. From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research. International Journal of Molecular Sciences. 2023;24(16):13021. doi:10.3390/ijms241613021
BibTeX
@article{Jiang2023,
author = {Jiang, Andrew and Handley, Renee R and Lehnert, Klaus and Snell, Russell G},
title = {From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {16},
pages = {13021},
doi = {10.3390/ijms241613021}
}
EUVIMED